BioTech to cost efficiency and a large , treatment-naïve patient pool . This is attracting more global pharmaceutical companies to conduct their trials in India .
Has the Indian CRO industry overcome the challenges it faced a decade ago ? Has it been able to maintain an edge within the APAC region especially when the CROs in countries like Korea , Australia and
overall average figure of 5.3 % per year .
When comparing Indian CROs to other APAC CROs , several factors come into play . In the area of clinical research , data management and biostatistics , India has a large pool of highly skilled professionals vis-a-vis any other APAC countries . In India , access to a genetically diverse and treatmentnaïve patient population is a significant advantage and Indian CROs leverage
China are acting as tough competition ?
The Asia-Pacific ( APAC ) region has continued to thrive as a growing hub for clinical trials in recent years . Despite the pandemic impact , between 2017 and 2022 , APAC posted a growth in clinical trials of around 14 %, outstripping growth in other major regions including the US , Europe and RoW . APAC ’ s growth far exceeded the the improved regulatory framework which is conducive for the conduct of clinical trials . Manpower costs and other expenses can vary significantly across the APAC region , with countries like Australia and Japan being much higher than India . Overall , Indian CROs maintain a competitive edge due to cost efficiency and a skilled workforce . In the last few years , India has
BIOVOICENEWS . COM 25